4-(Thiophen-2-yl)-1H-pyrrole-3-carbonitrile | 87388-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(Thiophen-2-yl)-1H-pyrrole-3-carbonitrile
• 英文别名: 4-thiophen-2-yl-1H-pyrrole-3-carbonitrile
• CAS: 87388-71-4
• 化学式: C₉H₆N₂S
• mdl: MFCD11218183
• 分子量: 174.226
• InChiKey: LSJKJYDXBQAZDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  407.8±40.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  对甲基苯磺酰甲基异腈 、 3-Oxo-2-(thiophen-2-ylmethylidene)butanenitrile 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以69%的产率得到2-acetyl-4-(thiophen-2-yl)-1H-pyrrole-3-carbonitrile
  参考文献：
  名称：

  串联Michael加成/异氰酸酯插入C-C键：2-酰基吡咯和中环稠合吡咯的新型获得途径†

  摘要：

  已经开发了一种新的反应模型，即串联式迈克尔加成反应/形式的异氰酸酯插入酰基C-C键。因此，在一次操作中，由甲基异氰化物与烯酮的反应合成了一系列的2-酰基吡咯和七元/八元环稠合的吡咯。

  DOI：

  10.1039/c3ob41793j

文献信息

• NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Toyoshima Takahiro

  公开号：US20090306396A1

  公开（公告）日：2009-12-10

  The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y 1 represents N or C(R 4 ); Y 2 represents N or C(R 5 ); R 4 and R 5 independently represent an alkyl group, a hydrogen atom etc.; one of R 1 and R 2 represents an optionally substituted aryl group, an alkoxy group or an optionally substituted heterocyclic group; the other of R 1 and R 2 represents a haloalkyl group, a cyano group, a halogen atom etc.; and R 3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

  本发明涉及具有黄嘌呤氧化酶抑制和尿酸排泄作用的新化合物以及包含其作为活性成分的药物组合物。即，本发明涉及以下通式（I）所代表的含氮杂环化合物： 其中，Y1代表N或C（R4）; Y2代表N或C（R5）; R4和R5独立地代表烷基，氢原子等；R1和R2中的一个代表可选取代的芳基，烷氧基或可选取代的杂环基；另一个代表卤代烷基，氰基，卤素原子等；R3代表5-四唑基或羧基，以及其药学上可接受的盐和包含其作为活性成分的药物组合物。
• 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shimizu Kazuo

  公开号：US20100227864A1

  公开（公告）日：2010-09-09

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M) 2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  本发明提供了一种化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）表示的具有黄嘌呤氧化酶抑制活性的5-成员杂环衍生物，其可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或其盐。在公式（I）中，T表示硝基、氰基等；环J表示芳基或杂芳基；Q表示羧基、5-四唑基等；Y表示H、OH、NH2、卤素、卤代烷基等；X1和X2独立地表示CR2或N；R2表示H、烷基等；R1表示卤素、氰基、卤代烷基、A-D-E-G-L-M、-N（-D-L-M）2等，在公式中，A表示单键、O、S等；D、G和M独立地表示可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E和L独立地表示单键、O、S、COO、SO2等。
• 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Shimizu Kazuo

  公开号：US20120289506A1

  公开（公告）日：2012-11-15

  5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, —N(-D-L-M) 2 and the like, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  通式（I）所表示的5元杂环衍生物具有黄嘌呤氧化酶抑制活性，并且可作为预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前药或盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，其中A表示单键，O，S等；D，G和M分别表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• US7947707B2
  申请人：——

  公开号：US7947707B2

  公开（公告）日：2011-05-24
• US8227500B2
  申请人：——

  公开号：US8227500B2

  公开（公告）日：2012-07-24